The Melanoma Letter Fall 2010, Vol. 28, No. 3

In this issue of The Melanoma Letter, Drs. Balch, Mihm, Gershenwald, and Soong provide a detailed evaluation of the revised AJCC melanoma staging system. A few important changes have occurred, including the addition of mitotic rate as an important prognostic factor in Stage I and II disease, the re-classification of patients with satellite or in-transit metastases from Stage IV to Stage III disease, and more.